Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Clinical colorectal cancer
- Publicado em
- 3 dez 2024
- Citações
- 3
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer
Julian Hamfjord, Tormod Kyrre Guren, Bengt Glimelius, Halfdan Sorbye, Per Pfeiffer, Olav Dajani, Ole Christian Lingjærde, Kjell Magne Tveit, Karen-Lise Garm Spindler, Niels Pallisgaard et al.
Descritores MeSH
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers, Tumor
- Colorectal Neoplasms
- Carcinoembryonic Antigen
- Circulating Tumor DNA
- Female
- Humans
- Male
- Middle Aged
- Mutation
Veja também
Estudos relacionados
- Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
- Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer
- Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study
- Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN Study